23.03.2017
MorphoSys AG DE0006632003
DGAP-News: MorphoSys's CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve as Interim CSO
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous
MorphoSys's CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to
Serve as Interim CSO (news with additional features)
23.03.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, March 23, 2017
MorphoSys's CSO Marlies Sproll Takes Temporary Leave
Markus Enzelberger to Serve as Interim CSO
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a
leader in the field of therapeutic antibodies, today announced that Dr.
Marlies Sproll, the Company's long-standing Chief Scientific Officer, will
be on temporary leave from her CSO position for family matters as of April
15, 2017. Dr. Sproll will take leave of absence from her function as member
of the Executive Board for a period of initially six months. She continues
to be a member of the Executive Board and will return to her CSO role as
soon as circumstances will allow.
The Supervisory Board of MorphoSys AG has named Dr. Markus Enzelberger as
Interim Chief Scientific Officer for the duration of Dr. Sproll's absence.
Dr. Enzelberger, who currently holds the position of Senior Vice President
Discovery Alliances and Technologies, is a chemist by training and has
closely worked together with Dr. Sproll for the past 15 years. Dr.
Enzelberger will assume the temporary CSO duties effective April 15, 2017.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment
of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a
few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit
http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R),
Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R)
and LanthioPep(R) are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these
forward-looking statements as far as the wording of the relevant press
release is concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=XNEPMMSLTB
Document title: Media Release
---------------------------------------------------------------------------
23.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
556287 23.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR